XAGE2 (Gene)

Organism:

Homo sapiens

Synonyms:CT12.2, ENTREZ:9502, GAGED3, HGNC:4112, MIM:300416, NM_130777, NP_570133, X antigen family member 2, XAGE-2, XAGE2, XAGE2B, XM_011530836, XP_011529138

Id:ENSG00000155622

Entrez:9502

Ensembl:ENSG00000155622

Description:X antigen family member 2

This gene is a member of the XAGE subfamily, which belongs to the GAGE family. The GAGE genes are expressed in a variety of tumors and in some fetal and reproductive tissues. This gene is strongly expressed in normal testis, and in Ewing's sarcoma, rhabdomyosarcoma, a breast cancer and a germ cell tumor. The protein encoded by this gene shares a sequence similarity with other GAGE/PAGE proteins. Because of the expression pattern and the sequence similarity, this protein also belongs to a family of CT (cancer-testis) antigens. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View XAGE2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with XAGE2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using XAGE2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for XAGE2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with XAGE2.

Results found

Linked to

	Label	Description
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216988 GSE216989 decitabine 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 1 GLUTATHIONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158458 2 V 1 SORAFENIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193751 1 V 3 ORIDONIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193739 CGA knockdown 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE216043 7 V 9 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE135514 8 V 7 DASATINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216988 GSE216989 decitabine 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 1 GLUTATHIONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158458 2 V 1 SORAFENIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE193751 1 V 3 ORIDONIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193739 CGA knockdown 2 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.